Entrada Therapeutics (TRDA) Balance Sheet: Assets & Liabilities

Entrada Therapeutics (TRDA) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Entrada Therapeutics reported total assets of $377.38M and total liabilities of $71.25M. Shareholders' equity was $306.13M, down 28.6% from $428.68M a year earlier. Total debt stood at $50.93M against $295.70M in cash and short-term investments, a net cash position of $244.77M. That puts debt-to-equity at 0.17, compared with 0.14 a year earlier.

Entrada Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Entrada Therapeutics, Inc. (TRDA) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	90.39	101.21	67.60	45.16	291.06	39.05	16.84
Short-Term Investments	205.30	318.79	284.37	143.56	0.00	0.00	0.00
Cash & Short-Term Investments	295.70	420.00	351.97	188.71	291.06	39.05	16.84
Accounts Receivable	1.18	3.68	5.88	0.60	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	9.38	16.36	11.92	21.16	7.64	0.90	0.59
Total Current Assets	306.25	440.04	369.77	209.88	298.70	39.95	17.44
Non-Current Assets
Property, Plant & Equipment (Net)	67.76	82.05	92.68	33.02	6.26	3.04	0.80
Other Non-Current Assets	3.36	4.23	6.74	9.16	0.87	0.54	0.00
Total Non-Current Assets	71.13	86.28	99.42	42.18	7.13	3.58	0.80
Total Assets	377.38	526.32	469.19	252.06	305.83	43.53	18.24
Current Liabilities
Accounts Payable	2.29	4.26	3.28	5.99	0.71	1.60	0.71
Short-Term Debt	4.14	7.56	7.91	8.41	0.00	0.00	0.00
Accrued Liabilities	17.68	13.34	3.66	2.08	6.01	1.64	-
Deferred Revenue	0.34	13.65	132.26	0.00	0.00	0.00	0.00
Other Current Liabilities	17.68	0.67	1.00	0.43	0.49	0.12	1.21
Total Current Liabilities	24.45	39.48	158.80	21.97	6.72	3.36	1.92
Non-Current Liabilities
Long-Term Debt	46.79	51.65	60.32	17.53	0.00	0.00	0.00
Other Non-Current Liabilities	0.00	6.51	7.72	0.00	0.40	81.66	31.84
Total Non-Current Liabilities	46.79	58.16	68.04	17.53	0.40	81.66	31.84
Total Liabilities	71.25	97.64	226.83	39.50	7.12	3.36	33.76
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-273.09	-129.34	-194.97	-188.29	-93.67	-42.51	-15.99
Accumulated Other Comprehensive Income	0.65	-0.04	0.20	-2.06	0.00	0.00	0.00
Additional Paid-in Capital	578.57	558.06	437.13	402.89	392.38	1.02	0.47
Shares Outstanding	38.28	37.57	33.44	31.39	31.22	-	-
Total Stockholders' Equity	306.13	428.68	242.36	212.55	298.72	40.17	-15.52
Total Liabilities & Equity	377.38	526.32	469.19	252.06	305.83	43.53	18.24

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Entrada Therapeutics Balance Sheet

How much debt does Entrada Therapeutics have?

Entrada Therapeutics had total debt of $50.93M as of Dec 31, 2025, against $295.70M in cash and short-term investments. Its debt-to-equity ratio was 0.17. Total debt was $59.21M a year earlier.

What are Entrada Therapeutics's total assets?

Entrada Therapeutics reported total assets of $377.38M as of Dec 31, 2025, down 28.3% from $526.32M a year earlier. Total liabilities were $71.25M.

What is Entrada Therapeutics's shareholders' equity?

Entrada Therapeutics's shareholders' equity was $306.13M as of Dec 31, 2025, or about $8.00 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition